BioCure Pharma's founder Dr.
Youngman Oh has developed a number of novel inventions in
the area of upper respiratory
disease, as well as oncology, specifically Radiation Therapy-Induced
Fibrosis (RTIF). BioCure Pharma's drug pipeline ranges from
pre-clinical studies to Phase II trials. The intellectual property
and patents held by BioCure and its subsidiaries, AltruGen
and InflammoGen, present many additional opportunities in key
areas such as cancer and diabetes.
Biocure Pharma'a
mission is to aggressively develop a new generation of drugs
that will vastly improve the quality of life of people suffering
from asthma-related diseases and post-operative radiation therapy.
By addressing each underlying disease state, our technologies
prevent and suppress, with a focus on safety and efficacy.
Tenancy
Virginia BioTechnology Research Park
Partners
Dr. Chet Leach, Pulmonary toxicologist
Lovelace Laboratories: non-clinical (canine efficacy, toxicity
and safety studies)
Virginia Commonwealth University
Virginia Biosciences Development Center
Services
Legal - Troutman Sanders (Richmond, VA)
Banking - Wachovia Bank
Accounting - Porte Brown (Chicago, IL) |
